EX-23.3 4 d540258dex233.htm EX-23.3

Exhibit 23.3

Consent of Independent Registered Public Accounting Firm

Acer Therapeutics Inc.

Newton, Massachusetts

We hereby consent to the use in the Prospectus constituting a part of this Registration Statement of our report dated March 27, 2023, relating to the financial statements of Acer Therapeutics Inc., which is contained in that Prospectus. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.

We also consent to the reference to us under the caption “Experts” in the Prospectus.

BDO USA, P.C.

Boston, Massachusetts

October 6, 2023